Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
IT0004147952
Mon, 13.05.2024
Newron Pharmaceuticals S.p.A.
Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients
Further study analysis reveals significant multi-domain benefits in PANSS and Clinical Global Impression of Change (CGI-C) ratings
Benefit on efficacy measures increased over time, suggesting larger [ … ]
Tue, 30.04.2024
Newron Pharmaceuticals S.p.A.
Newron announces positive top-line results
from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
Primary endpoint and key secondary endpoint of study met; drug was well tolerated, with no safety concerns identified
Glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizoph [ … ]
Tue, 19.03.2024
Newron Pharmaceuticals S.p.A.
Newron presents 2023 financial results and provides 2024 outlook
Milan, Italy, March 19, 2024, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financ [ … ]
Fri, 15.03.2024
Newron Pharmaceuticals S.p.A.
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
EIB agrees to extend repayment dates of tranches one to three of its loan to the Company until end of 2025 and into 2026, after potentially significant pipeline milestones
Amended agreement envisages [ … ]
Thu, 14.03.2024
Newron Pharmaceuticals S.p.A.
Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares
Proceeds of up to EUR 15.0* million
Milan, Italy, March 14, 2024, 17:45 CET – Newron Pharmaceuticals S.p.A. (“Newron”, or the “Company”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients [ … ]
Thu, 04.01.2024
Newron Pharmaceuticals S.p.A.
Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)
Treatment with evenamide demonstrated significant, clinically important, progressive, sustained and long-lasting improvement on PANSS total, CGI-S and Level of Functioning (LOF)
More than 70% of patients experienced clinically im [ … ]
Fri, 29.12.2023
Newron Pharmaceuticals S.p.A.
Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide
290 patients participate at study centers in Europe, Asia and Latin America
Results from the study are expected in March 2024
Milan, Italy, December 29, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5) [ … ]
Mon, 09.10.2023
Newron Pharmaceuticals S.p.A.
Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria
40% of patients no longer met TRS severity criteria
Company presented data from study in treatment resistant schizophrenia (TRS) confirming therapeutic durability and efficacy at the 36th ECNP Congress in Bar [ … ]
Wed, 04.10.2023
Newron Pharmaceuticals S.p.A.
Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress
Poster presentations will include the full results from all 161 patients randomized in study 014 at the six-month time point from extension study 015, a Phase II trial evalu [ … ]
Mon, 02.10.2023
Newron Pharmaceuticals S.p.A.
Newron appoints Margarita Chavez as board advisor
Margarita Chavez, former Managing Director at AbbVie Ventures, to be nominated for election to the Board of Directors at the Ordinary AGM 2024
Milan, Italy, October 2, 2023 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development [ … ]